NASDAQ · Biotechnology

OKYO (OKYO) Stock

$1.65 -0.60% NASDAQ: OKYO Healthcare

Valuation

MetricValue
Price$1.65
Market Cap$63.31M
P/E Ratio-13.17
P/B Ratio4.37
P/S Ratio0.00
EPS (TTM)$-0.12
52-Week High$3.35
52-Week Low$1.42
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-103.44%
ROA-21.99%
ROCE-56.53%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.44

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-6.0M$-13.0M$-16.0M$-7.0M$-8.0M
Net Profit$-5.0M$-13.0M$-17.0M$-5.0M$-9.0M
EPS$-0.36$-0.60$0.00$-0.12$-0.24
Op Margin—————

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$4.0M$5.0M$2.0M$4.0M$21.0M
Total Liabilities$1.0M$7.0M$7.0M$9.0M$9.0M
Cash$3.0M$4.0M$1.0M$2.0M$15.0M
Borrowings$0$2.0M$0$0$0

Latest News

OKYO Pharma advances toward Phase 3 FDA trial - ICYMI Proactive · Jul 11, 2026 OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain Proactive · Jul 8, 2026 OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain MT Newswires · Jul 8, 2026 OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain GlobeNewswire · Jul 8, 2026 OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain Proactive · Jul 7, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-5.0M$-8.0M$-9.0M$-2.0M$-6.0M
Investing Cash Flow$0$0$0$0$-6.0M
Financing Cash Flow$1.0M$9.0M$0$0$0
Net Cash Flow$-4.0M$1.0M$-3.0M$1.0M$13.0M
Free Cash Flow$-5.0M$-8.0M$-9.0M$-2.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.29
EV / EBITDA-4.24
FCF Yield-5.61%
Quick Ratio2.43
Interest Coverage-33.23
Return 1Y-46.55%
Return 3Y25.64%
Return 5Y—

Ownership

Insiders Held30.41%
Institutions Held20.81%
Institutions Float Held29.91%
Institutional HolderSharesReport Date
Woodline Partners LP3,652,1902026-03-31
Maven Securities Limited1,175,5352026-03-31
Stonepine Capital Management, LLC850,0002026-03-31
Balyasny Asset Management LP584,7962026-03-31
UBS Group AG59,7602026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANEBAnebulo Pharmaceuticals, Inc. $0.34 +0.00% -1.73 $13.72M 0.00%
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%
MGNX $3.78 +3.00% -2.92 $240.27M 0.00%

About OKYO

OKYO is led by CEO Robert J. Dempsey, employs 3 people, headquartered in GB, publicly traded since 2022.

OKYO stock trades at $1.65 with a market capitalization of $63.31M. The stock is valued at a price-to-earnings (P/E) ratio of -13.17, price-to-book of 4.37, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.42 and $3.35, and currently trades 50.7% below its 52-week high.

On profitability, OKYO generates a return on equity (ROE) of -103.44%, return on capital employed of -56.53%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides